news aktuell GmbH

R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics

Del

Gaining new market segments in clinical diagnostics – globally unique position as system supplier in laboratory diagnostics sector.

Darmstadt, June 7, 2022 – R-Biopharm AG, a leading German biotechnology company operating on a global scale, announced the acquisition of AusDiagnostics. R-Biopharm is expanding its product portfolio with the addition of the Australian specialist and manufacturer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment. The company is thereby unlocking new market segments in clinical diagnostics and continuing on its path of steady internationalization. “The existing and future molecular biology multiplex analysis platforms for syndrome testing from system supplier AusDiagnostics broadens our molecular biology expertise and perfectly complements our present clinical diagnostics portfolio,” states Christian Dreher, CEO of R-Biopharm. “The acquisition strengthens our position as a reliable partner for system solutions and offers our customers additional options for diagnostics.”

Upon its establishment in 2006, the Australian company introduced its patented Multiplex Tandem PCR (MT-PCR) on the market. The current technology allows the simultaneous detection of up to 24 pathogens or resistance genes from a single sample, thus shortening the lengthy test procedure in human and animal diagnostics as well as environmental, agricultural, and food analysis. The analysis platform is used in laboratories and hospitals throughout the world for detecting a broad range of diseases.

AusDiagnostics CEO Scott Gilroy said that the transaction marked an exciting new chapter for the company: “Both AusDiagnostics and R-Biopharm AG share the same commitment to innovation in the biotechnology space. This acquisition strengthens AusDiagnostics and will accelerate our global presence. We’ve experienced tremendous, industry-leading growth over the past two years, which has been underpinned by our broad suite of innovative products, talented team, and incredible, loyal customers. Joining the R-Biopharm group will allow us to further build on this and continue to deliver exceptional products and service for our Australian and international customers.”

AusDiagnostics currently has 92 employees with offices in New Zealand, the USA, and Great Britain. Its production facilities in Australia and Great Britain supply a steadily growing network of more than 25 distributors and partners around the world – from which R-Biopharm expects further synergy effects for production as well as international service and support in its clinical diagnostics line.


About R-Biopharm

R-Biopharm AG, located in Darmstadt, is one of Germany’s leading biotechnology companies. It considers itself as a pioneer for health and quality of life. The compa­ny´s aspiration is to provide the highest possible precision, safety, clarity and certainty with excellent products and solutions – in prevention, therapy and healing. Research and development at R-Biopharm has developed agile processes in order to take on new challenges to accompany a steadily growing world population into a new health era with sustainable solutions.

As an internationally recognized leader, R-Biopharm stands for the development of excellent technologies, products and solutions in the fields of Clinical Diagnostics, Nutrition Care and Food and Feed Analytics. R-Biopharm is the global market leader for test systems in the field of allergen analysis. The biotechnology company is known for its products that are of high importance for human health. To this end, it unites development, production and sales under one roof and is successfully represented in more than 120 countries worldwide – through 28 subsidiaries and 120 distributors. Founded in 1988, the family-run company employs a total of around 1,300 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the “Sustainability Award” for sustainable and profitable growth. R-Biopharm is cultivating a value-oriented corporate culture and management and is family-run in the second generation. The Chairman of the Board of Directors is Christian Dreher.


Press contact:

Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/

R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de 

Bilder

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din epostadresse under for å få de nyeste sakene fra news aktuell GmbH på epost fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

EUROJET signs contract with NETMA to provide 48 new EJ200 engines for the Spanish Air Force24.6.2022 08:43:34 CEST | Pressemelding

ILA Berlin Air Show, Thursday, 23 June 2022, 16:00 EUROJET Turbo GmbH (EUROJET), the consortium responsible for the EJ200 engine installed in the Eurofighter Typhoon, has today signed a contract with the NATO Eurofighter & Tornado Management Agency (NETMA) to provide 48 new EJ200 engines for the Spanish Air Force. The contract, signed at the ILA Berlin Air Show, between General Miguel Ángel Martín Pérez, General Manager of NETMA and Gerhard Bähr, CEO of EUROJET, covers EJ200 engines for the Eurofighter Typhoon fighter aircraft as part of Project Halcón. The aircraft will enter service on the Canary Islands, adding to the existing Spanish fleet of 70 Eurofighters. In common with all EJ200 engines for the Spanish Air Force, final assembly of the engines will be conducted by ITP Aero at their Ajalvir facility with deliveries scheduled from 2024 onwards. Production of the engine modules will be performed by the four partner companies of the EUROJET consortium; Rolls-Royce, MTU Aero Engines

ZINTINUS: Food tech on its way to reshaping a multi trillion market21.6.2022 13:49:57 CEST | Pressemelding

Bain & ZINTINUS: “The food sector is at a tipping point, about to grow exponentially” Transforming the global food sector to a more sustainable industry is important to improve consumer health and reduce the sector’s carbon footprint – it is also a means to secure food supply The transition of the food system opens enormous opportunity for value creation and thus also for entrepreneurs and investors Berlin & New York, June 21, 2022 – The transformation of the world’s food market towards a more sustainable model is now at a tipping point, within an annual global food market of US $ 8 trillion. Food sector transformation relies on innovation to deliver healthier diets, environmental-friendly production, and more sustainable food practices. A transformation of this size offers an opportunity of historic proportions, concludes a white paper co-authored by two seasoned food experts from Bain & Company and ZINTINUS, a food tech investment fund. “Transforming the global food sector into a mor

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom